CG oncology

Forecast & Rating15 analysts currently cover CG oncology, with about 93.3% giving a positive rating — meaning they expect the stock to rise. The average price target is $91.08, about 25.9% upside from the current price of $72.35. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 35.2% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study CG oncology closely still see room for the stock to rise. Data as of Sep 11, 2026; for reference only and not investment advice.